S Ioacara1,2, C Guja1,3, O Georgescu2, S Martin1,2, A Sirbu1,2, M Purcaru2, S Fica1,2. 1. "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 2. "Elias" University Emergency Hospital, Bucharest, Romania. 3. "N.C. Paulescu" National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, Romania.
Abstract
AIMS: To investigate the effect of sulphonylurea (SU) treatment on all-cause and cardiovascular mortality as compared with metformin (MET), when used in combination with insulin (INS) in type 2 diabetes. METHODS: All type 2 diabetes patients aged ≥40 years were included at their first prescription of INS+MET or INS+SU, during 2001-2008. They were considered at risk until death or December 31st, 2011. Mortality rates were calculated per 1000 person-years. Crude and adjusted rate ratios (RR) were calculated using time dependent analysis with INS+MET as reference. RESULTS: There were 7122 patients (60.8% women) included in the analysis, with a mean age at baseline of 62.0±9.9 years. During the 11 years of study, patients on INS+MET contributed 13620 person-years and 330 deaths (mortality rate 24, CI95% 22-27), while those on INS+SU contributed 8720 person-years and 393 deaths (mortality rate 45, CI95% 41-50). Adjusted all-cause mortality RR were: SU 1.6 (CI95% 1.21-2.11, p<0.001), glimepiride 1.18 (CI95% 0.73-1.91, p=0.51), gliclazide 1.78 (CI95% 1.07-2.95, p=0.024), glibenclamide 1.66 (CI95% 0.71-3.88, p=0.23), glipizide 1.24 (CI95% 0.68-2.27, p=0.49), and gliquidonum 2.32 (CI95% 1.54-3.50, p=0.001). CONCLUSIONS: When combined with insulin as dual therapy, patients treated with SU were at increased mortality risk as compared with insulin + MET.
AIMS: To investigate the effect of sulphonylurea (SU) treatment on all-cause and cardiovascular mortality as compared with metformin (MET), when used in combination with insulin (INS) in type 2 diabetes. METHODS: All type 2 diabetes patients aged ≥40 years were included at their first prescription of INS+MET or INS+SU, during 2001-2008. They were considered at risk until death or December 31st, 2011. Mortality rates were calculated per 1000 person-years. Crude and adjusted rate ratios (RR) were calculated using time dependent analysis with INS+MET as reference. RESULTS: There were 7122 patients (60.8% women) included in the analysis, with a mean age at baseline of 62.0±9.9 years. During the 11 years of study, patients on INS+MET contributed 13620 person-years and 330 deaths (mortality rate 24, CI95% 22-27), while those on INS+SU contributed 8720 person-years and 393 deaths (mortality rate 45, CI95% 41-50). Adjusted all-cause mortality RR were: SU 1.6 (CI95% 1.21-2.11, p<0.001), glimepiride 1.18 (CI95% 0.73-1.91, p=0.51), gliclazide 1.78 (CI95% 1.07-2.95, p=0.024), glibenclamide 1.66 (CI95% 0.71-3.88, p=0.23), glipizide 1.24 (CI95% 0.68-2.27, p=0.49), and gliquidonum 2.32 (CI95% 1.54-3.50, p=0.001). CONCLUSIONS: When combined with insulin as dual therapy, patients treated with SU were at increased mortality risk as compared with insulin + MET.
Authors: Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: M Monami; D Balzi; C Lamanna; A Barchielli; G Masotti; E Buiatti; N Marchionni; E Mannucci Journal: Diabetes Metab Res Rev Date: 2007-09 Impact factor: 4.876
Authors: Tina Ken Schramm; Gunnar Hilmar Gislason; Allan Vaag; Jeppe Nørgaard Rasmussen; Fredrik Folke; Morten Lock Hansen; Emil Loldrup Fosbøl; Lars Køber; Mette Lykke Norgaard; Mette Madsen; Peter Riis Hansen; Christian Torp-Pedersen Journal: Eur Heart J Date: 2011-04-06 Impact factor: 29.983
Authors: Kevin M Pantalone; Michael W Kattan; Changhong Yu; Brian J Wells; Susana Arrigain; Anil Jain; Ashish Atreja; Robert S Zimmerman Journal: Diabetes Care Date: 2010-03-09 Impact factor: 19.112
Authors: Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; David R Matthews; H Andrew W Neil Journal: N Engl J Med Date: 2008-09-10 Impact factor: 91.245
Authors: Josie M M Evans; Simon A Ogston; Frank Reimann; Fiona M Gribble; Andrew D Morris; Ewan R Pearson Journal: Diabetes Obes Metab Date: 2007-12-17 Impact factor: 6.577
Authors: S Akin; C Bölük; Y Ozgur; N Aladağ; G Geçmez; O Keskin; U Turk Boru; M Tasdemir Journal: Acta Endocrinol (Buchar) Date: 2019 Jul-Sep Impact factor: 0.877